Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
EDISON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...